



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

XU *et al.*

Appl. No. 09/914,046

Filed: October 1, 2001

For: **Antibody Fragment-Targeted
Immunoliposomes for Systemic
Gene Delivery**

Confirmation No.: 8537

Art Unit: 1644

Examiner: Dibrino, M.

Atty. Docket: 2474.0010001/BJD/JKM

Amendment and Reply Under 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated June 9, 2006, Applicants submit the following Amendments and Remarks. In accordance with 37 C.F.R. § 1.121, this Amendment and Reply is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims; and
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this

paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.